Prices delayed by at least 15 minutes | Print
CRISPR Therapeutics AG (CRSP)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), whichis a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Address
Aeschenvorstadt 36
Basel
CHE
4051
Telephone
+1 339 9702843
Forecast key dates
| Name | Key Date |
|---|---|
| CRISPR Therapeutics AG Fourth Quarter Earnings Results for 2024 | 2025-02-21T00:00:00 |
| CRISPR Therapeutics AG Annual Report for 2024 | 2025-02-21T00:00:00 |
| CRISPR Therapeutics AG Third Quarter Earnings Results for 2024 | 2024-11-06T00:00:00 |
| CRISPR Therapeutics AG Second Quarter Earnings Results for 2024 | 2024-08-07T00:00:00 |
| CRISPR Therapeutics AG Annual General Meeting for 2024 | 2024-06-07T02:00:00 |
| CRISPR Therapeutics AG First Quarter Earnings Results for 2024 | 2024-05-08T00:00:00 |
| CRISPR Therapeutics Annual Needham Virtual Healthcare Conference 2024 | 2024-04-10T11:45:00 |
Previous key dates
| Name | Key Date |
|---|---|
| CRISPR Therapeutics Annual Needham Virtual Healthcare Conference 2024 | 2024-04-10T11:45:00 |
| CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit | 2024-02-21T13:00:00 |
| CRISPR Therapeutics AG Fourth Quarter Earnings Results for 2023 | 2024-02-21T00:00:00 |
| CRISPR Therapeutics AG Annual Report for 2023 | 2024-02-21T00:00:00 |
| CRISPR Therapeutics AG Third Quarter Earnings Results for 2023 | 2023-11-06T00:00:00 |
| CRISPR Therapeutics AG Second Quarter Earnings Results for 2023 | 2023-08-07T00:00:00 |
| CRISPR Therapeutics AG Annual General Meeting for 2023 | 2023-06-08T02:00:00 |
| CRISPR Therapeutics AG First Quarter Earnings Results for 2023 | 2023-05-08T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.